Related Experiment Videos
Cytokines as new treatment targets in chronic heart failure
Jan Kristian Damås1, Lars Gullestad, Pål Aukrust
1Department of Cardiology, Rikshospitalet, Oslo, Norway. j.k.damas@klinmed.uio.no
Insights
Inflammatory cytokines impact heart failure. Targeting these with therapies like tumor necrosis factor-alpha (TNF-alpha) or intravenous immunoglobulin (IVIG) shows promise for improving heart function in chronic heart failure (CHF).
Area of Science:
- Cardiology
- Immunology
- Pharmacology
Background:
- Inflammatory cytokines negatively affect myocardial contractility and remodeling in chronic heart failure (CHF).
- Conventional cardiovascular drugs have limited impact on the cytokine network in CHF.
- There is growing interest in anticytokine therapies for CHF management.
Purpose of the Study:
- To explore the potential of anticytokine therapies in managing chronic heart failure (CHF).
- To evaluate the efficacy of targeting inflammatory cytokines for improved myocardial performance.
Main Methods:
- Review of small studies investigating tumor necrosis factor-alpha (TNF-alpha) as a therapeutic target.
- Analysis of studies using intravenous immunoglobulin (IVIG) for its anti-inflammatory effects.
- Assessment of immunomodulatory approaches in CHF.
Main Results:
- Targeting TNF-alpha has shown improvements in functional capacity and myocardial performance.
- IVIG's impact on myocardial performance correlates with its anti-inflammatory effects.
- Immunomodulation shows potential as an adjunctive therapy for CHF.
Conclusions:
- Anticytokine therapies and immunomodulation represent promising therapeutic avenues for CHF.
- Further research is needed to identify the most effective drugs for cytokine-targeted therapy in CHF.
- These approaches may complement conventional cardiovascular treatments for chronic heart failure.
Abstract:
Inflammatory cytokines may negatively influence contractility and contribute to the remodelling process in the failing myocardium. Traditional cardiovascular drugs appear to have little influence on the overall cytokine network in chronic heart failure (CHF). Increased interest in anticytokine therapy has therefore evolved. Several small studies have used tumour necrosis factor (TNF)-alpha as a target, resulting in improved functional capacity and myocardial performance. Intravenous immunoglobulin (IVIG) represents another therapeutic approach in which the impact on myocardial performance appears to be correlated with anti-inflammatory effects. These studies demonstrate potential for immunomodulation as a therapy in addition to conventional cardiovascular treatment in CHF, but the most effective drugs in this regard have yet to be identified.